Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expression.
暂无分享,去创建一个
D. Ehrnhoefer | M. Hayden | B. Leavitt | M. Pouladi | X. W. Yang | R. Graham | R. Friedlander | P. Paganetti | N. Bissada | Yuanyun Xie | N. Skotte | Dagmar E. Ehrnhoefer | Jeong Eun Kim | Y. Xie | Niels H. Skotte
[1] M. Aschner,et al. Disease‐toxicant screen reveals a neuroprotective interaction between Huntington’s disease and manganese exposure , 2010, Journal of neurochemistry.
[2] H. D. Rosas,et al. Single-step detection of mutant huntingtin in animal and human tissues: a bioassay for Huntington's disease. , 2009, Analytical biochemistry.
[3] J. Willey,et al. PRESTROKE PHYSICAL ACTIVITY IS ASSOCIATED WITH SEVERITY AND LONG-TERM OUTCOME FROM FIRST-EVER STROKE , 2009, Neurology.
[4] S. Harper. Progress and challenges in RNA interference therapy for Huntington disease. , 2009, Archives of neurology.
[5] P. Brundin,et al. Beyond the brain: widespread pathology in Huntington's disease , 2009, The Lancet Neurology.
[6] C. Bult,et al. Aging in inbred strains of mice: study design and interim report on median lifespans and circulating IGF1 levels , 2009, Aging cell.
[7] I. Martins,et al. Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.
[8] A. O’Sullivan,et al. Short-term oral oestrogen therapy dissociates the growth hormone/insulin-like growth factor-I axis without altering energy metabolism in premenopausal women. , 2009, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.
[9] Anne-Catherine Bachoud-Lévi,et al. Neuroendocrine Disturbances in Huntington's Disease , 2009, PloS one.
[10] G. Bonvento,et al. Sustained effects of nonallele‐specific Huntingtin silencing , 2009, Annals of neurology.
[11] Beate Sick,et al. Dysregulation of Gene Expression in Primary Neuron Models of Huntington's Disease Shows That Polyglutamine-Related Effects on the Striatal Transcriptome May Not Be Dependent on Brain Circuitry , 2008, The Journal of Neuroscience.
[12] Martin Drozda,et al. Inhibitors of Cytochrome c Release with Therapeutic Potential for Huntington's Disease , 2008, The Journal of Neuroscience.
[13] M. Hayden,et al. Accumulation of N-terminal mutant huntingtin in mouse and monkey models implicated as a pathogenic mechanism in Huntington's disease. , 2008, Human molecular genetics.
[14] Carlos Cepeda,et al. Full-Length Human Mutant Huntingtin with a Stable Polyglutamine Repeat Can Elicit Progressive and Selective Neuropathogenesis in BACHD Mice , 2008, The Journal of Neuroscience.
[15] J. Lüdemann,et al. Reference ranges of serum IGF-1 and IGFBP-3 levels in a general adult population: results of the Study of Health in Pomerania (SHIP). , 2008, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.
[16] K. G. Rajeev,et al. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits , 2007, Proceedings of the National Academy of Sciences.
[17] Roger L Albin,et al. Longitudinal Evaluation of the Hdh (CAG)150 Knock-In Murine Model of Huntington's Disease , 2007, The Journal of Neuroscience.
[18] Alexandra Durr,et al. Early Energy Deficit in Huntington Disease: Identification of a Plasma Biomarker Traceable during Disease Progression , 2007, PloS one.
[19] S. Tabrizi,et al. Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates. , 2007, Journal of proteome research.
[20] F. Walker. Huntington's disease , 2007, The Lancet.
[21] S. Humbert,et al. Huntington’s disease: from huntingtin function and dysfunction to therapeutic strategies , 2006, Cellular and Molecular Life Sciences CMLS.
[22] M. Hayden,et al. Body weight is modulated by levels of full-length huntingtin. , 2006, Human molecular genetics.
[23] L. Raymond,et al. Levels of mutant huntingtin influence the phenotypic severity of Huntington disease in YAC128 mouse models , 2006, Neurobiology of Disease.
[24] Elena Cattaneo,et al. Normal huntingtin function: an alternative approach to Huntington's disease , 2005, Nature Reviews Neuroscience.
[25] Magdalena Zernicka-Goetz,et al. Cleavage pattern and emerging asymmetry of the mouse embryo , 2005, Nature Reviews Molecular Cell Biology.
[26] I. Kanazawa,et al. Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA , 2005, Neuroscience Research.
[27] R. Mandel,et al. Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.
[28] M. Hayden,et al. Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[29] Sarah J Tabrizi,et al. Gene expression in Huntington's disease skeletal muscle: a potential biomarker. , 2005, Human molecular genetics.
[30] M. Hayden,et al. Loss of wild-type huntingtin influences motor dysfunction and survival in the YAC128 mouse model of Huntington disease. , 2005, Human molecular genetics.
[31] H. Paulson,et al. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[32] O. Gavrilova,et al. Studies involving the GH-IGF axis: Lessons from IGF-I and IGF-I receptor gene targeting mouse models. , 2005, Journal of endocrinological investigation.
[33] Fabrice P Cordelières,et al. Huntingtin Controls Neurotrophic Support and Survival of Neurons by Enhancing BDNF Vesicular Transport along Microtubules , 2004, Cell.
[34] A. Ochoa,et al. Assessment of the nutrition status of patients with Huntington's disease. , 2004, Nutrition.
[35] B. Seed,et al. A PCR primer bank for quantitative gene expression analysis. , 2003, Nucleic acids research.
[36] Martin Drozda,et al. Depletion of wild‐type huntingtin in mouse models of neurologic diseases , 2003, Journal of neurochemistry.
[37] Andrea Crotti,et al. Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes , 2003, Nature Genetics.
[38] E. Simpson,et al. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. , 2003, Human molecular genetics.
[39] Charles Kooperberg,et al. Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain. , 2002, Human molecular genetics.
[40] J. Olson,et al. Polyglutamine and transcription: gene expression changes shared by DRPLA and Huntington's disease mouse models reveal context-independent effects. , 2002, Human molecular genetics.
[41] D. Rubinsztein. Lessons from animal models of Huntington's disease. , 2002, Trends in genetics : TIG.
[42] L. Raymond,et al. Increased Sensitivity to N-Methyl-D-Aspartate Receptor-Mediated Excitotoxicity in a Mouse Model of Huntington's Disease , 2002, Neuron.
[43] Manjit,et al. Neurology , 1912, NeuroImage.
[44] J. Olson,et al. Early transcriptional profiles in huntingtin-inducible striatal cells by microarray analyses. , 2002, Human molecular genetics.
[45] M. MacDonald,et al. The HD mutation causes progressive lethal neurological disease in mice expressing reduced levels of huntingtin. , 2001, Human molecular genetics.
[46] A. Reiner,et al. Neurons Lacking Huntingtin Differentially Colonize Brain and Survive in Chimeric Mice , 2001, The Journal of Neuroscience.
[47] Blair R. Leavitt,et al. Loss of Huntingtin-Mediated BDNF Gene Transcription in Huntington's Disease , 2001, Science.
[48] R. Albin,et al. Neurological abnormalities in a knock-in mouse model of Huntington's disease. , 2001, Human molecular genetics.
[49] M. MacDonald,et al. Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells. , 2000, Human molecular genetics.
[50] Michael S. Levine,et al. Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice , 2000, Nature Genetics.
[51] René Hen,et al. Reversal of Neuropathology and Motor Dysfunction in a Conditional Model of Huntington's Disease , 2000, Cell.
[52] Claire-Anne Gutekunst,et al. A YAC Mouse Model for Huntington’s Disease with Full-Length Mutant Huntingtin, Cytoplasmic Toxicity, and Selective Striatal Neurodegeneration , 1999, Neuron.
[53] D. Borchelt,et al. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. , 1999, Human molecular genetics.
[54] C. Roberts,et al. The IGF system : molecular biology, physiology, and clinical applications , 1999 .
[55] J. Hodgson,et al. Human huntingtin derived from YAC transgenes compensates for loss of murine huntingtin by rescue of the embryonic lethal phenotype. , 1996, Human molecular genetics.
[56] S. W. Davies,et al. Exon 1 of the HD Gene with an Expanded CAG Repeat Is Sufficient to Cause a Progressive Neurological Phenotype in Transgenic Mice , 1996, Cell.
[57] James F. Gusella,et al. Differential Expression of Normal and Mutant Huntington's Disease Gene Alleles , 1996, Neurobiology of Disease.
[58] Y. Agid,et al. Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias , 1995, Nature.
[59] S. Hersch,et al. Identification and localization of huntingtin in brain and human lymphoblastoid cell lines with anti-fusion protein antibodies. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[60] C. Ross,et al. Expression of the Huntington's disease (IT15) protein product in HD patients. , 1995, Human molecular genetics.
[61] E. Hirsch,et al. Cellular localization of the Huntington's disease protein and discrimination of the normal and mutated form , 1995, Nature Genetics.
[62] I. Kanazawa,et al. Abnormal gene product identified in Huntington's disease lymphocytes and brain. , 1995, Biochemical and biophysical research communications.
[63] C. Rosen,et al. Tamoxifen and estrogen lower circulating lipoprotein(a) concentrations in healthy postmenopausal women. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.
[64] Peter S. Harper,et al. Huntington's disease , 1991 .
[65] R. Hochberg,et al. A simple and sensitive microtiter plate estrogen bioassay based on stimulation of alkaline phosphatase in Ishikawa cells: estrogenic action of delta 5 adrenal steroids. , 1990, Endocrinology.
[66] L. M. Morales,et al. Nutritional evaluation of Huntington disease patients. , 1989, The American journal of clinical nutrition.
[67] R. Ferrante,et al. Neuropathological Classification of Huntington's Disease , 1985, Journal of neuropathology and experimental neurology.
[68] C. Tamminga,et al. Twenty-four hour plasma levels of growth hormone and prolactin in Huntington's disease. , 1983, Journal of neurology, neurosurgery, and psychiatry.
[69] M. Molitch,et al. Human growth hormone and somatomedin C suppress the spontaneous release of growth hormone in unanesthetized rats. , 1983, Endocrinology.
[70] C. Tamminga,et al. Plasma growth hormone and prolactin response to dopaminergic GABAmimetic and cholinergic stimulation in Huntington's disease , 1983, Neurology.
[71] I. Bone,et al. Studies of hypothalamic function in Huntington's chorea. , 1981, Journal of neurology, neurosurgery, and psychiatry.
[72] E. Parati,et al. Growth hormone hyperresponsiveness to dopaminergic stimulation in Huntington's chorea. , 1979, Neuroendocrinology.
[73] W. Tourtellotte,et al. Growth hormone and prolactin secretion in Huntington's disease. , 1979, Life sciences.
[74] D. Cocchi,et al. Altered growth hormone and prolactin responses to dopaminergic stimulation in Huntington's chorea. , 1977, The Journal of clinical endocrinology and metabolism.
[75] O. Phillipson,et al. Plasma growth hormone concentrations in Huntington's chorea. , 1976, Clinical science and molecular medicine.
[76] W. R. Sulaiman,et al. Altered growth hormone release in Huntington's chorea. , 1976, Journal of neurology, neurosurgery, and psychiatry.